Patient Capital Management’s DXC Technology DXC Stock Holding History

Patient Capital Management’s Portfolio DXC Stock Details DXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,198,173	Closed	-$25M	–	44
2023 Q3	$25M	Buy	1,198,173 +1,095,323	+1,065%	+$25.1M	1.46%	30
2023 Q2	$2.75M	Buy	102,850 +42,850	+71%	+$1.07M	0.15%	36
2023 Q1	$1.53M	Sell	60,000 -100,600	-63%	-$2.74M	0.68%	38
2022 Q4	$4.26M	Sell	160,600 -29,400	-15%	-$818K	2.07%	25
2022 Q3	$4.65M	Sell	190,000 -81,600	-30%	-$2.24M	2.32%	19
2022 Q2	$8.23M	Sell	271,600 -30,000	-10%	-$931K	3.65%	8
2022 Q1	$9.84M	Sell	301,600 -22,100	-7%	-$731K	3.33%	6
2021 Q4	$10.4M	Buy	+323,700	New	+$10.5M	3%	7

Other funds holding DXC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Patient Capital Management's DXC Position: Q4 2023 in Review

Patient Capital Management sold out of DXC Technology (DXC) in Q4 2023, closing a stake of 1,198,173 shares — an estimated $25M sold.

Patient Capital Management first reported a position in DXC in Q4 2021 and held it in 8 quarters. The position peaked at $25M in Q3 2023. 433 funds tracked by Wall St. Rank hold DXC as of Q4 2023.

Patient Capital Management reported no remaining DXC Technology position as of Q4 2023 after selling out during the quarter.
Patient Capital Management sold 1,198,173 DXC Technology shares in Q4 2023, an estimated $25M.
Patient Capital Management first reported a position in DXC Technology in Q4 2021 and held it in 8 quarters.
Patient Capital Management's DXC Technology position peaked at $25M in Q3 2023.
433 funds tracked by Wall St. Rank held DXC Technology as of Q4 2023.

Based on Patient Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.